Fjarde Ap-fonden’s Novavax NVAX Stock Holding History

Fjarde Ap-fonden’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-23,100	Closed	-$1.7M	–	556
2022 Q1	$1.7M	Hold	23,100	–	–	0.02%	535
2021 Q4	$3.31M	Hold	23,100	–	–	0.03%	488
2021 Q3	$4.79M	Sell	23,100 -800	-3%	-$176K	0.04%	411
2021 Q2	$5.07M	Buy	+23,900	New	+$4.38M	0.05%	408

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fjarde Ap-fonden's NVAX Position: Q2 2022 in Review

Fjarde Ap-fonden sold out of Novavax (NVAX) in Q2 2022, closing a stake of 23,100 shares — an estimated $1.7M sold.

Fjarde Ap-fonden first reported a position in NVAX in Q2 2021 and held it in 4 quarters. The position peaked at $5.07M in Q2 2021. 325 funds tracked by Wall St. Rank hold NVAX as of Q2 2022.

Fjarde Ap-fonden reported no remaining Novavax position as of Q2 2022 after selling out during the quarter.
Fjarde Ap-fonden sold 23,100 Novavax shares in Q2 2022, an estimated $1.7M.
Fjarde Ap-fonden first reported a position in Novavax in Q2 2021 and held it in 4 quarters.
Fjarde Ap-fonden's Novavax position peaked at $5.07M in Q2 2021.
325 funds tracked by Wall St. Rank held Novavax as of Q2 2022.

Based on Fjarde Ap-fonden's 13F filing for Q2 2022, filed 21 Jul 2022.